Genscript Biotech Co. (OTCMKTS:GNNSF – Get Free Report) fell 14.7% during trading on Monday . The company traded as low as C$1.57 and last traded at C$1.57. 15,000 shares changed hands during trading, an increase of 28% from the average session volume of 11,700 shares. The stock had previously closed at C$1.84.
Genscript Biotech Trading Down 14.7%
The stock’s fifty day moving average is C$1.93 and its two-hundred day moving average is C$2.10.
About Genscript Biotech
GenScript Biotech Corporation is a global contract research, development and manufacturing organization (CDMO) specializing in synthetic biology and biopharmaceutical services. Founded in 2002, the company provides end-to-end solutions that span gene and peptide synthesis, recombinant protein expression, custom antibody discovery and cell line development. GenScript’s integrated platforms support early-stage discovery through to process development, enabling academic institutions, biotech innovators and pharmaceutical companies to accelerate research timelines.
The company’s core offerings include molecular biology services such as DNA construction, gene editing using CRISPR/Cas9 technology and high-throughput peptide libraries.
Featured Articles
- Five stocks we like better than Genscript Biotech
- The buying spree that no one is talking about
- How to collect $500-$800 weekly (BlackRock’s system)
- Trump’s AI Secret: 100X Faster Than Nvidia
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Your Bank Account Is No Longer Safe
Receive News & Ratings for Genscript Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genscript Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
